FDA plans to review Vivus's anti-obesity drug Qnexa in July
This article was originally published in Scrip
Executive Summary
Vivus said an FDA advisory committee is tentatively scheduled to review the company's NDA for its anti-obesity drug Qnexa (phentermine plus topiramate) on 15 July. The panel would be the endocrinologic and metabolic drugs advisory committee.